Skip to main content
. 2020 Aug 13;9(8):72. doi: 10.1038/s41389-020-00257-z

Fig. 4. Persistence of PD-L1-CAR T cells in mice.

Fig. 4

a Experimental design of HCC827-Fluc tumors with PD-L1-CAR T-cell therapy and re-challenge. b Serial bioluminescence imaging of tumor progression and regression. c, d Bioluminescence kinetics of HCC827-Fluc tumors (n = 5 mice per group). For the CD19-CAR T cell control group, a separated cohort of NSG mice was challenged with HCC-827-Fluc cells at day 70.